title: Newer developments in the immunotherapy of malignant melanoma.
abstract: Individuals with malignant melanoma present a variety of immune abnormalities including but not limited to cellular immune dysfunction, antigen presentation deficits, and cytokine production defects. Therefore, enhancing the immune system potential represents an appealing avenue for melanoma therapy. The authors review the immune therapies currently in clinical use as well as the most promising immunotherapy candidates. Ipilimumab, a monoclonal antibody against the CTLA-4, was approved for the therapy of advanced melanoma in 2011. In addition, sizeable anti-melanoma activity has recently been shown with the use of other agents including anti-PD-1/anti-PD-1 ligand antibodies. Consequently, these experimental immunotherapy agents may soon become important items in the anti-melanoma armamentarium.
authors: Department of Medicine, Yale University School of Medicine, New Haven, CT, USA.
authors: Benjamin
authors: B
authors: Maslin
authors: Doru T
authors: DT
authors: Alexandrescu
authors: Thomas E
authors: TE
authors: Ichim
authors: Constantin A
authors: CA
authors: Dasanu
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use*; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors; D006801:Humans; D007167:Immunotherapy; D000074324:Ipilimumab; D008545:Melanoma / Q000276:immunology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; D000074324:Ipilimumab
keywords: Malignant melanoma; anti-CTLA-4 antibodies; anti-PD-1 antibodies; immunotherapy; ipilimumab